• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自身免疫性疾病,对皮质类固醇和免疫抑制剂有抗药性。

Autoimmune diseases refractory to corticosteroids and immunosuppressants.

机构信息

Research and Development Department, Taro Pharmaceutical Industries Ltd, Haifa, Israel.

出版信息

Front Immunol. 2024 Sep 16;15:1447337. doi: 10.3389/fimmu.2024.1447337. eCollection 2024.

DOI:10.3389/fimmu.2024.1447337
PMID:39351223
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11439723/
Abstract

Corticosteroids and immunosuppressive drugs can alleviate the symptoms of most autoimmune diseases and induce remission by restraining the autoimmune attack and limiting the damage to the target tissues. However, four autoimmune non-degenerative diseases-adult advanced type 1 diabetes mellitus, Hashimoto's thyroiditis, Graves' disease, and advanced primary biliary cholangitis-are refractory to these drugs. This article suggests that the refractoriness of certain autoimmune diseases is due to near-total loss of secreting cells coupled with the extremely low regenerative capacity of the affected tissues. The near-complete destruction of cells responsible for secreting insulin, thyroid hormones, or biliary HCO diminishes the protective effects of immunosuppressants against further damage. The slow regeneration rate of these cells hinders tissue recovery, even after drug-induced immune suppression, thus preventing remission. Although the liver can fully regenerate after injury, severe primary biliary cholangitis may impair this ability, preventing liver recovery. Consequently, these four autoimmune diseases are resistant to immunosuppressive drugs and corticosteroids. In contrast, early stages of type 1 diabetes and early primary biliary cholangitis, where damage to secreting cells is partial, may benefit from immunosuppressant treatment. In contrast to these four diseases, chronic degenerative autoimmune conditions like multiple sclerosis may respond positively to corticosteroid use despite the limited regenerative potential of the affected tissue (the central nervous system). The opposite is true for acute autoimmune conditions like Guillain-Barré syndrome.

摘要

皮质类固醇和免疫抑制剂可以通过抑制自身免疫攻击和限制对靶组织的损伤来缓解大多数自身免疫性疾病的症状并诱导缓解。然而,四种自身免疫性非退行性疾病——成人晚期 1 型糖尿病、桥本甲状腺炎、格雷夫斯病和晚期原发性胆汁性胆管炎——对这些药物有抗药性。本文认为,某些自身免疫性疾病的抗药性是由于分泌细胞几乎完全丧失,同时受影响组织的再生能力极低所致。负责分泌胰岛素、甲状腺激素或胆汁 HCO₃⁻的细胞几乎完全被破坏,降低了免疫抑制剂对进一步损伤的保护作用。这些细胞的再生速度较慢,即使在药物诱导的免疫抑制后,也会阻碍组织的恢复,从而阻止疾病缓解。虽然肝脏在受伤后可以完全再生,但严重的原发性胆汁性胆管炎可能会损害这种能力,阻止肝脏的恢复。因此,这四种自身免疫性疾病对抗免疫抑制剂和皮质类固醇有抗性。相比之下,1 型糖尿病和早期原发性胆汁性胆管炎的早期阶段,分泌细胞的损伤是部分的,可能受益于免疫抑制剂治疗。与这四种疾病相反,慢性退行性自身免疫性疾病,如多发性硬化症,尽管受影响组织(中枢神经系统)的再生潜力有限,但可能对皮质类固醇的使用有积极反应。急性自身免疫性疾病,如格林-巴利综合征,情况则恰恰相反。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54ef/11439723/32152830cedf/fimmu-15-1447337-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54ef/11439723/32152830cedf/fimmu-15-1447337-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54ef/11439723/32152830cedf/fimmu-15-1447337-g001.jpg

相似文献

1
Autoimmune diseases refractory to corticosteroids and immunosuppressants.自身免疫性疾病,对皮质类固醇和免疫抑制剂有抗药性。
Front Immunol. 2024 Sep 16;15:1447337. doi: 10.3389/fimmu.2024.1447337. eCollection 2024.
2
A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.一项评估胆钙化醇补充对桥本甲状腺炎自身免疫可能作用的前瞻性研究。
J Assoc Physicians India. 2023 Jan;71(1):1.
3
Drugs in autoimmune diseases.自身免疫性疾病中的药物。
Klin Wochenschr. 1990;68 Suppl 21:15-25.
4
Mycophenolate mofetil for maintenance of remission in steroid-dependent autoimmune pancreatitis.霉酚酸酯治疗依赖激素的自身免疫性胰腺炎的缓解维持。
World J Gastroenterol. 2012 May 14;18(18):2287-90. doi: 10.3748/wjg.v18.i18.2287.
5
Vitamin D 1alpha-hydroxylase (CYP1alpha) polymorphism in Graves' disease, Hashimoto's thyroiditis and type 1 diabetes mellitus.维生素D 1α-羟化酶(CYP1α)基因多态性与格雷夫斯病、桥本甲状腺炎及1型糖尿病的关系
Eur J Endocrinol. 2002 Jun;146(6):777-81. doi: 10.1530/eje.0.1460777.
6
Clustering of additional autoimmunity behaves differently in Hashimoto's patients compared with Graves' patients.与格雷夫斯病患者相比,桥本甲状腺炎患者的自身免疫性疾病聚类表现不同。
Eur J Endocrinol. 2011 May;164(5):789-94. doi: 10.1530/EJE-10-1172. Epub 2011 Mar 4.
7
Serum concentration of soluble Fas in patients with autoimmune thyroid diseases.自身免疫性甲状腺疾病患者血清可溶性Fas浓度
Thyroid. 1998 Jan;8(1):43-7. doi: 10.1089/thy.1998.8.43.
8
Hashimoto's thyroiditis following Graves' disease.格雷夫斯病后发生的桥本甲状腺炎。
Acta Med Indones. 2010 Jan;42(1):31-5.
9
Management of primary biliary cirrhosis and autoimmune cholangitis.原发性胆汁性肝硬化和自身免疫性胆管炎的管理
Clin Liver Dis. 1998 May;2(2):333-51, ix. doi: 10.1016/s1089-3261(05)70011-8.
10
Analysis of Polymorphisms rs7093069-IL-2RA, rs7138803-FAIM2, and rs1748033-PADI4 in the Group of Adolescents With Autoimmune Thyroid Diseases.分析青少年自身免疫性甲状腺疾病患者中 rs7093069-IL-2RA、rs7138803-FAIM2 和 rs1748033-PADI4 的多态性。
Front Endocrinol (Lausanne). 2020 Oct 23;11:544658. doi: 10.3389/fendo.2020.544658. eCollection 2020.

引用本文的文献

1
Clinical features and outcomes of nine children with acute necrotizing encephalopathy.9例急性坏死性脑病患儿的临床特征及预后
Front Pediatr. 2025 Aug 6;13:1615960. doi: 10.3389/fped.2025.1615960. eCollection 2025.
2
CAR T-cells meet autoimmune neurological diseases: a new dawn for therapy.嵌合抗原受体T细胞与自身免疫性神经疾病:治疗的新曙光
Front Immunol. 2025 Jul 18;16:1604174. doi: 10.3389/fimmu.2025.1604174. eCollection 2025.
3
MK2 Inhibition as a Novel Treatment for Fibrosis in Primary Sclerosing Cholangitis via an IL-22-Dependent Mechanism.

本文引用的文献

1
Immune tolerance and the prevention of autoimmune diseases essentially depend on thymic tissue homeostasis.免疫耐受和自身免疫性疾病的预防从根本上取决于胸腺组织的稳态。
Front Immunol. 2024 Mar 20;15:1339714. doi: 10.3389/fimmu.2024.1339714. eCollection 2024.
2
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.EULAR 推荐的系统性红斑狼疮治疗:2023 更新版。
Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762.
3
Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions.
通过白细胞介素-22依赖性机制抑制MK2作为原发性硬化性胆管炎纤维化的新型治疗方法。
Cells. 2025 Jul 5;14(13):1031. doi: 10.3390/cells14131031.
4
New insights into the phenomenon of remissions and relapses in autoimmune diseases and the puzzle of benign autoantibodies in healthy individuals.对自身免疫性疾病缓解和复发现象以及健康个体中良性自身抗体之谜的新见解。
Front Immunol. 2025 May 9;16:1522356. doi: 10.3389/fimmu.2025.1522356. eCollection 2025.
5
Construction of patient trajectories to model clinical trial outcomes: Application to Myasthenia Gravis.构建患者轨迹以模拟临床试验结果:在重症肌无力中的应用。
medRxiv. 2025 Apr 16:2025.04.11.25325663. doi: 10.1101/2025.04.11.25325663.
6
Glucocorticoid receptor epigenetic activity in the heart.心脏中糖皮质激素受体的表观遗传活性。
Epigenetics. 2025 Dec;20(1):2468113. doi: 10.1080/15592294.2025.2468113. Epub 2025 Feb 25.
7
Emerging Mechanisms and Biomarkers Associated with T-Cells and B-Cells in Autoimmune Disorders.自身免疫性疾病中与T细胞和B细胞相关的新机制及生物标志物
Clin Rev Allergy Immunol. 2025 Feb 11;68(1):14. doi: 10.1007/s12016-025-09022-9.
不同免疫介导疾病中的低剂量静脉注射免疫球蛋白(IVIg)。
Autoimmun Rev. 2023 Nov;22(11):103451. doi: 10.1016/j.autrev.2023.103451. Epub 2023 Sep 23.
4
Emerging Therapeutic Strategies in The Fight Against Primary Biliary Cholangitis.原发性胆汁性胆管炎治疗新策略
J Clin Transl Hepatol. 2023 Aug 28;11(4):949-957. doi: 10.14218/JCTH.2022.00398. Epub 2023 Mar 16.
5
Prevention of Type 1 Diabetes in Children: A Worthy Challenge?预防儿童 1 型糖尿病:一项值得挑战的目标?
Int J Environ Res Public Health. 2023 May 26;20(11):5962. doi: 10.3390/ijerph20115962.
6
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.阿巴西普治疗 1 型糖尿病高危 1 期患者的进展:一项随机、双盲、对照试验。
Diabetes Care. 2023 May 1;46(5):1005-1013. doi: 10.2337/dc22-2200.
7
Type 1 : A Review on Advances and Challenges in Creating Insulin Producing Devices.类型1:关于制造胰岛素生产设备的进展与挑战的综述
Micromachines (Basel). 2023 Jan 6;14(1):151. doi: 10.3390/mi14010151.
8
Identification of Immune Microenvironment Changes and the Expression of Immune-Related Genes in Liver Cirrhosis.鉴定肝硬化中的免疫微环境变化和免疫相关基因的表达。
Front Immunol. 2022 Jul 12;13:918445. doi: 10.3389/fimmu.2022.918445. eCollection 2022.
9
Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment.桥本甲状腺炎:病因、诊断和治疗的循证指南。
Pol Arch Intern Med. 2022 Mar 30;132(3). doi: 10.20452/pamw.16222. Epub 2022 Mar 3.
10
Immunosuppressive drugs modes of action.免疫抑制剂作用机制。
Best Pract Res Clin Gastroenterol. 2021 Oct-Dec;54-55:101757. doi: 10.1016/j.bpg.2021.101757. Epub 2021 Jun 16.